Randomized phase II study of Erlotinib vs. S-1 for non-small lung cancer after failure of two or three prior

Not Applicable

• Conditions: on-small-cell lung cancer

• Registration Number: JPRN-UMIN000005308
• Lead Sponsor: Hokkaido Lung Cancer Clinical Study Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

1)Previous histories of drug allergy, which may increase the risk of this study. 2)Serious concomitant infection. 3)Usages of oral steroids or immunosuppressive drugs. 4)Serious complications including severe cardiovascular disease, cerebrovascular disease, severe hypertension, active peptic ulcer, uncontrolled diabetes. 5)Interstitial pneumonia or pulmonary fibrosis on chest CT scans. 6)Patients with EGFR mutation or having past history of administration of EGFR tyrosine kinase inhibitors. 7)Severe pleural, abdominal or cardiac effusion. 8) Patients with symptomatic brain metastasis 9)Patients with active concomitant malignancy 10)Pregnant, lactating women. 11)Inappropriate patients judged by physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease control rate

Secondary Outcome Measures

Name	Time	Method
Overall survival Progression free survival Response rate Safty